Across TCGA pan-cancer cohorts, MBLAC2 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated MBLAC2 data layer compared with 25 for mass-spec protein and 4 for mass-spec protein.
The strongest signal is observed in colon adenocarcinoma (COAD), where higher MBLAC2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MBLAC2 expression acts as an unfavorable survival marker.
COAD, LIHC, and UCEC are the cancer types where MBLAC2 Mutation most reproducibly stratifies survival.